Four Colorado physicians are named in a lawsuit settlement involving pharmaceutical company Biohaven, which allegedly paid ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

As weight loss drugs continue to grow in popularity in the U.S., some health leaders are warning about fake drugs on the ...

With this latest announcement, Lilly has committed to investing more than $50 billion in U.S. manufacturing since 2020.

Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...

Eli Lilly and Company, UnitedHealth Group, AbbVie, Walmart, Johnson & Johnson, Natera, and Gilead Sciences are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool.

California dedicated $100 to manufacturing insulin for diabetic residents. That effort is taking longer than Gov. Gavin ...

The University of Copenhagen is excited to announce TruDiagnostic, a leader in epigenetic testing, will present its latest ...

A bevy of major corporations and foreign countries have pledged to pour billions into the U.S. since President Donald Trump ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit ...